Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1988-8-23
|
| pubmed:abstractText |
Cardiotoxicity is supposed to be the most important limiting factor in chemotherapy with anthracycline derivatives. The left ventricular ejection fraction was measured several times by means of radionuclid - scintigraphy in 24 patients treated with epirubicin - cisplatinum. Pathologic values have been found only in 3 patients, but no correlation with age, cumulative dose or dose/m2 of body surface could be demonstrated.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0044-4197
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
110
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
429-32
|
| pubmed:dateRevised |
2008-2-11
|
| pubmed:meshHeading |
pubmed-meshheading:3164959-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3164959-Cardiac Output,
pubmed-meshheading:3164959-Cardiomyopathies,
pubmed-meshheading:3164959-Cisplatin,
pubmed-meshheading:3164959-Doxorubicin,
pubmed-meshheading:3164959-Epirubicin,
pubmed-meshheading:3164959-Female,
pubmed-meshheading:3164959-Humans
|
| pubmed:year |
1988
|
| pubmed:articleTitle |
[On the problem of the cardiotoxicity of epirubicin-cisplatin].
|
| pubmed:affiliation |
Universitäts-Klinik für Frauenheilkunde, Universitäts-Klinik für Nuklearmedizin, Innsbruck.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|